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Abstract
Mesenchymal stromal cell (MSC)-based therapy holds great promise for treating immune disorders and for
regenerative medicine in agreement with their paracrine trophic and immunosuppressive activities. Various
processes have been developed worldwide to produce clinical grade MSCs but, so far, it is not known if one given
MSC is more efficient than another. In addition, while their broad activity on innate and adaptative immune cell
subsets is now widely admitted, the precise mechanisms supporting their immunoregulatory capacities are still a
matter of debate. Finally, quantitative immunological potency assays correlated to clinical efficacy and clinically
relevant immunomonitoring approaches for MSC-treated patients are sorely needed. Multiple parameters could
influence the immunomodulatory potential of therapeutic MSCs. The most important challenge is now to
differentiate, within a high number of poorly comparable and even contradictory pre-clinical studies, the
parameters that could have some clinical impact from those that are only due to uncontrolled experimental
variability. Importantly, besides MSC-related differences, primarily linked to production processes, several important
variables associated with immune assays themselves, including selection of effector immune cells, activation signals,
and read-out techniques, should be carefully considered to obtain solid results with potential therapeutic
application. In this review, we establish a core of common and reproducible immunological properties of MSCs,
shed light on technical issues concerning immunomodulatory potential assessment, and put them into perspective
when considering clinical application.
Introduction
Interest in adult mesenchymal stromal cells (MSC) as a
promising tool in regenerative medicine and for treating se-
vere immune-mediated diseases has increased over the past
decade [1]. Whereas human tissue-resident MSCs are
poorly characterized, the possibility to expand ex vivo high
numbers of clinical-grade MSCs has paved the way for their
therapeutic use. In agreement, more than 250 clinical trials
evaluating MSC therapy have been registered and prelimin-
ary encouraging results - which should now be confirmed
in large randomized phase II/III trials - have been recently
reported in graft-versus-host-disease, fistulating Crohn’s
disease, progressive multiple sclerosis, kidney transplant
rejection, and ischemic cardiomyopathy [2-6]. The increas-
ing use of MSCs has led to the development of large-scale
production processes according to good manufacturing
practice (GMP) requiring a strict monitoring of all critical
aspects classically associated with cell therapy products [7].
In addition, expansion of clinical-grade MSCs involves spe-
cific parameters, in particular tissue sources and culture
conditions. Besides the poorly acknowledged influence of
donor-related variability, MSCs can be readily obtained
from either bone marrow or adipose tissue and some
discrepancies have already been reported in phenotypic,
proteomic, transcriptomic, and differentiation profiles
between bone marrow-derived MSCs (BM-MSCs) and
adipose-derived MSCs (ADSCs) [8-10]. In addition, no con-
sensus has emerged on the best MSC culture conditions,
including: starting from unfractionated cells versus cells se-
lected by density-gradient separation or by cell-sorting
based on specific surface markers; use of fetal calf serum
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versus human platelet lysate; cell seeding density; and num-
ber of population doubling that accurately reflects the scale
of cell expansion and determines culture-related senes-
cence. The potential impact of these parameters on product
fitness and function remains a matter of debate.
It is now widely accepted that the clinical potential of
MSCs essentially relies on their short-term paracrine
ability to reduce inflammation, inhibit immune re-
sponses, and produce trophic factors. Any variability in
the MSC production process could contribute to a
modulation of their immune properties. In addition, the
great diversity of experimental protocols used to moni-
tor MSC immune properties favors result inconstancy,
thus blurring global interpretation of the data [11]. Im-
portantly, besides the general concerns about the validity
of mouse models, major interspecies differences amongst
the molecular pathways supporting immunoregulatory
activity of murine versus human MSCs have been
reported [12], making it crucial to design fully validated
in vitro immunological assays. Such coordinated efforts
would be helpful to better understand the mechanism of
action of GMP-grade MSCs and optimize their further
clinical use.
Immunoregulatory properties of mesenchymal
stromal cells: common features
MSCs exert their immunoregulatory effects on a large
panel of effector cells of adaptive and innate immunity,
including T cells, B cells, natural killer cells, monocytes/
macrophages, dendritic cells and neutrophils [1,13].
They have been shown to arrest activated T cells in the
G0/G1 phase of the cell cycle and to decrease their pro-
duction of IFN-γ and IL-2, to downregulate cytotoxic T
lymphocyte-mediated cytotoxicity, to favor the growth of
natural regulatory T cells, and to drive CD4pos T cells,
including fully differentiated Th17, into regulatory
phenotype and function. Similarly, MSCs alter the prolif-
eration, cytotoxicity, and IFN-γ production of natural
killer (NK) cells, and γδ T cells [14,15]. Furthermore,
they interfere with the differentiation of dendritic cells,
and impair their maturation into fully functional
antigen-presenting cells [16]. Similarly, MSCs promote a
macrophage reprogramming towards an IL-10posTNF-
αneg M2-like phenotype, associated with tissue repair
and tumor progression [17-19].
Importantly, inhibition of immune cells relies essen-
tially on a combination of soluble factors that are not
constitutively expressed by MSCs but are induced fol-
lowing MSC priming by inflammatory stimuli [20]. Con-
versely, resting MSCs have supportive and antiapoptotic
activities towards various cell types, including T cells, B
cells, NK cells and neutrophils [21-23]. As a conse-
quence, resting MSCs favor the survival and prolifera-
tion of highly purified activated B cells, which do not
produce IFN-γ, whereas previous treatment of MSCs
with exogenous IFN-γ converts them into a B-cell in-
hibitory phenotype [23]. The net effect of MSCs on B-
cell differentiation remains unclear [24]. In addition,
MSCs could behave as antigen-presenting cells in some
specific contexts, a property that could favor immune re-
jection and low persistence in vivo [25]. IFN-γ plays a
pivotal role, in collaboration with TNF-α and IL-1α/β,in
the triggering of the inhibitory machinery of MSCs [20].
MSCs display a wide range of inhibitory mechanisms
that are essentially redundant in their pathways of
induction and functional consequences. Among them,
the tryptophan-catabolizing enzyme indoleamine 2,3-
dioxygenase (IDO) appears as the most robust T-cell
and B-cell inhibitory system induced by IFN-γ in human
MSCs, whereas mouse MSCs preferentially use inducible
nitric oxide synthase [12]. Similarly, IL-10-dependent
production of soluble HLA-G5 molecule by human
MSCs was involved in the expansion of regulatory T
cells [26], whereas no murine homologue of HLA-G has
been identified. Among the most reproducibly reported
immunoregulatory pathways activated in primed human
MSCs, one should also highlight prostaglandin-E2,
which is supposed to play a pivotal role in NK inhibition
[14], and TNF-α-induced protein 6 (TSG-6), which in-
fluences neutrophil extravasation directly and through
the inhibition of Toll-like receptor (TLR)-dependent
activation of resident macrophages [27,28]. Interestingly,
TSG-6 is the only MSC-derived factor described so far
as sufficient per se to reproduce the therapeutic activity
of MSCs in several animal models of cardiac, lung, and
cornea injury [28-30]. Finally, it should be noted that a
common property of human and mouse MSCs is their
capacity to produce, in particular after stimulation by IFN-
γ and TNF-α, high levels of inflammatory chemokines that
may recruit immune cells into close proximity with inhibi-
tory MSCs [31,32].
Immunoregulatory properties of mesenchymal
stromal cells: experimental pitfalls
Although the headlines of MSC immunoregulatory
properties are quite well defined, the wide heterogeneity
of in vitro experimental settings has generated disparate
and poorly comparable results, thus limiting both the
general interest and the clinical impact of these studies.
In addition, lack of standardization could lead to a loss
of insightful information embedded in uncontrolled
technical variability. Two main variables could apply to
the conundrum at hand: MSC-related parameters and
immune cell-related parameters (Figure 1).
Considering MSC-related parameters, we already
underlined that studies dealing with murine MSCs could
essentially not be directly transposed to human MSCs.
In addition, we and others have recently demonstrated
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that human MSC source and culture conditions could
modulate their capacity to inhibit immune response
[33], indicating that a careful description of all culture
parameters, as required for GMP-grade production, is
mandatory to interpret immunological data. Of note,
large studies comparing ADSCs and BM-MSCs obtained
from the same donors using identical procedures are still
lacking so no definitive conclusions can be made on the
direct impact of cell sources on MSC properties. A
major concern remains inter-individual variability, since
phenotypically indistinguishable MSCs produced from
healthy donors could display strongly different capacities
to produce cytokines and respond to inflammatory li-
censing [18,34]. As recently stated by the International
Society for Cellular Therapy (ISCT) MSC committee,
GMP-grade MSC immune properties should be vali-
dated using both resting and primed cells, in agreement
with their use in local or systemic inflammatory clinical
settings [11]. Whatever the selected licensing stimulus,
its composition and kinetic should be carefully standard-
ized. A combination of IFN-γ and TNF-α for 40 hours
has been proposed as the standard MSC licensing proto-
col but TLR ligands are also well known to variably
modify MSC immune properties and should be consid-
ered depending on the specific clinical application [20].
Another crucial parameter is the cell culture expan-
sion evaluated by the cumulative number of population
doubling. Large-scale expansion could be theoretically
associated with genetic instability, even if human MSCs,
unlike murine MSCs, do not transform in vitro [11,35].
Moreover, it could also give rise to loss of differentiation
potential, clonal selection, and replicative senescence, a
process that could modulate immune properties [36,37].
In particular, senescence-associated secretory phenotype
is characterized by the release of numerous inflamma-
tory cytokines, chemokines, and growth factors [38].
Interestingly, whereas the MSC dose did not affect re-
sponse rate in patients treated for steroid-resistant graft-
versus-host disease, infusion of early passage MSCs was
correlated to both better response and better survival
when compared with late passage MSCs [39]. The func-
tional consequences of senescence-related modifications
on MSC immunoregulatory potential remain to be fully
elucidated. The impact of donor-related variability and
replicative senescence is probably even more pre-
eminent when considering industry-sponsored MSC tri-
als in which a single donor sample is used to produce
large lots of numerous cell doses (universal donor ap-
proach), whereas academic-driven trials use minimally
expanded MSCs (one donor/one recipient approach)
MSC-related parameters
Immune cell-related parameters
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Figure 1 Critical parameters for assessment of mesenchymal stromal cell immunomodulatory potential. Multiple factors could impact the
study of mesenchymal stromal cell (MSC) immunomodulatory capacities, including MSC-based and immune cell-based variables. Standardization
of these parameters is of utmost importance to ensure reproducibility of the experiments. B, B cells; CTL, cytotoxic T lymphocytes; DC, dendritic
cells; MO, monocytes/macrophages; NK, natural killer cells; PD, population doubling; PMN, polymorphonuclear neutrophils; Th, T helper cells.
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[40]. Importantly, the number of passages is a poorly re-
liable parameter to evaluate MSC lifespan, and deter-
mination of cumulative population doubling should be
systematically recorded as a standardized cell qualifica-
tion control.
Finally, an underestimated source of variability is the
cryopreservation of MSCs. Almost all clinical trials use
cryopreserved MSCs immediately after thawing. Recent
studies suggest that MSCs thawed for less than 24 hours
display reduced immune suppressive properties in vitro
[41]. Immunological assays should thus clearly specify
whether MSCs are cryopreserved products or not and
whether a post-thawing ‘rescue’ phase has been used.
When focusing on immune cell-related parameters, a
precise description of the most important variables is
also required, including strict qualification of effector
immune cells, use of various MSC to immune cell ratios,
definition of reproducible immune cell activation signals,
and use of fully validated read-out techniques, including
appropriate internal controls [11,33]. First, the use of
negatively selected highly purified immune cell subsets
instead of whole peripheral blood mononuclear cells
should be favored to avoid confounding effects of third-
party cells on both immune cell and MSC activation sta-
tus. In order to increase result reproducibility, in par-
ticular when comparing GMP-grade MSC batches in
quantitative assays, the use of cryopreserved batches of
functionally validated T, B, and NK cells, or monocytes
is helpful to reduce technical variability. Particular
attention should be paid to the purification of peripheral
blood neutrophils since the time between blood
harvesting and cell processing, the purification proced-
ure, as well as the presence of minute amounts of
endotoxin could significantly alter their functions. Im-
portantly, high viability and high proliferative capacity of
T, B, and NK cells are required to avoid interference
with the antiapoptotic activity of MSCs and subtle alter-
ations of these parameters can profoundly affect the bio-
logical conclusions. In this respect, as various stimuli
have been used to activate immune cells, including mito-
gens, cytokines, polyclonal activation of antigen receptor,
and specific antigens, an important recommendation is
to set up the best parameters for optimal cell activation
and minimal cell death (culture medium, duration of the
stimulation, composition of the stimulatory cocktail).
Importantly, whereas B-cell receptor or T-cell receptor
triggering is completely B-cell or T-cell specific, several
stimuli regularly used to activate immune cells trigger
simultaneous activation of MSCs, leading to a more
complex interpretation of the results. This is particularly
the case for TLR3 and TLR4 ligands, which are conveni-
ent activators of myeloid cells but can also act on MSCs.
Finally, a detailed description of the read-out techniques
and interpretation is also mandatory. To date, no
phenotypic marker has been reliably demonstrated as
predictive for MSC immunoregulatory potential. In
agreement, a recent working proposal of the ISCT MSC
committee reviews the most frequently used functional
in vitro assays to evaluate the interplay between MSCs
and various immune cell subsets [11].
Among the various mechanisms involved in the im-
munosuppressive activity of human MSCs, IDO plays a
pivotal role in both inhibition of T-cell and B-cell prolif-
eration and induction of IL-10-producing M2 macro-
phages [18]. IDO can be evaluated at several levels: RNA
by quantitative PCR; protein by western blot or im-
munofluorescence; activity by quantification of trypto-
phan and kynurenin in culture supernatant; and
function by the use of its highly specific chemical inhibi-
tor, the L-1 methyltryptophan. In keeping with the mul-
tiple levels of regulation of IDO, we found no link
between IDO mRNA level and T-cell inhibition but a
good correlation exists between the capacity of MSCs to
suppress T cells and to express IDO protein and enzym-
atic activity after inflammatory licensing [18,33]. Since
quantification of IDO catalytic activity in response to in-
creasing dose of IFN-γ is easy to standardize, it could be
useful as a quantitative qualification control for selection
of MSC donors, or GMP culture processes. Of course,
other inhibitory pathways could be also explored, using
specific chemical inhibitors and/or small interfering
RNA strategies.
Immunoregulatory properties of mesenchymal
stromal cells: unsolved questions
Whereas an increasing number of recently published pa-
pers have focused on the inhibition of immune re-
sponses by MSCs, few have developed strategies to
understand how immune cells modify MSC properties
in turn. Besides the well-recognized licensing role of im-
mune cell-derived IFN-γ, several other soluble and
membrane factors could have a direct impact on MSC
immune plasticity. As an example, B/T cell-derived
lymphotoxin is involved in the differentiation of ADSCs
into lymphoid stromal cells that regulate immune cell
homing and activation within secondary lymphoid or-
gans through expression of chemokines, cytokines, and
adhesion molecules [42]. Similarly, CD40L activates
NF-κB signaling in MSCs and triggers expression of
inflammatory cytokines whereas IL-4 strongly induces
the expression of CD106 (our unpublished data). It is
tempting to speculate that, as described for tumor cell/
stromal cell crosstalk, the contact with variably activated
immune cells in vivo could drive MSC immune
polarization.
Such mechanisms are currently under evaluation
in vitro but the physiological role of native MSCs as
immunosuppressive cells and their capacity to receive
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immune cell-derived signals remain questionable. The
recent demonstration that hematopoietic stem cell niche
should be considered as a localized immune-privileged
site maintained by regulatory T cells raises the question
of the role of MSCs in this process [43]. Conversely,
perivascular BM-MSCs could sense circulating TLR li-
gands and, by producing CCL2, modulate the frequency
of bloodstream inflammatory CCR2pos monocytes, thus
enhancing antimicrobial defense but also potentially ex-
acerbating noninfectious inflammatory diseases [44].
These results suggest that the immunological properties
of native MSCs are highly complex, in particular when
considering the heterogeneous stromal cell compartment
derived from resident MSCs. The field would clearly
benefit from the ability to prospectively isolate and
characterize relatively pure native stromal cell subsets. A
better understanding of the immunomodulatory poten-
tial of native MSCs would be highly helpful to design
more relevant assays for the qualification of GMP-grade
MSCs.
Another important clinical question is to ensure that
no significant adverse effects are caused by infusion of
immunosuppressive cultured MSCs. In the context of
allogeneic stem cell transplantation, how MSCs might
inhibit antimicrobial immune response in profoundly
immunosuppressed patients is a matter of concern
[39,45]. However, human MSCs, unlike mouse MSCs,
exhibit potent IDO-dependent antimicrobial properties
[46]. In fact, the degree of tryptophan depletion required
for suppression of microbial growth is far less stringent
than that required for T-cell inhibition. Theoretically,
MSCs have also the potential to favor cancer progression
since they are recruited to sites of neoplasias, integrate
into the tumor-associated stroma, release growth factors,
angiogenic molecules and metalloproteinases, and sup-
press anti-tumor immune response. However, no in-
crease of leukemia relapse has been reported after MSC-
based graft-versus-host disease treatment [39], probably
in part due to the lack of persistence of these cells
in vivo. Further investigations with regard to the poten-
tial adverse effects of MSC infusion in the context of co-
existence or previous diagnosis of neoplastic diseases
should be undertaken.
Immunoregulatory properties of mesenchymal
stromal cells: clinical applications
Analyzing how and to what extent GMP-grade MSCs
could inhibit immune responses could have several clin-
ical applications. First, it will allow the selection of the
‘best’ MSCs - that is, identification of appropriate donors
and production processes. As for allogeneic MSCs, valid-
ation of the process could involve complex phenotypic
and functional assays, including mechanistic analyses,
since it is performed before the beginning of clinical
trials, and could be used at least in part in building a
dossier for regulatory authorities. However, release cri-
teria applicable to each MSC batch should be restrained
to short-term, fully quantitative pivotal assays. Of course,
aliquots of GMP-grade MSCs may be cryopreserved
throughout clinical trials to investigate retrospectively
new immune markers. The main goal now is to correlate
in vitro immune assay results with clinical efficacy, in
order to define true potency assays that are currently
lacking. This will require both fully standardized in vitro
assays and fully standardized clinical trials. To date, the
only parameter significantly correlated to T-cell inhib-
ition is the capacity of MSCs to produce active IDO
[18,33] but it remains to be firmly demonstrated in
forthcoming clinical trials that in vitro quantification of
IFN-γ-induced IDO activity is a good surrogate bio-
logical marker of in vivo clinical potency.
Another important issue is the design of relevant
immunomonitoring approaches. Whereas MSCs are es-
sentially rapidly cleared in vivo, they are supposed to ini-
tiate immune modifications that will amplify their direct
initial activity. Proportion of regulatory T cells, modula-
tion of T-cell polarization balance, and plasma levels of
inflammatory cytokines and chemokines could be useful
to document inflammation dampening. Quantification of
IDO activity in plasma should also be evaluated in this
context [47]. As previously described in cancer immuno-
therapy, collection of biopsies after local MSC adminis-
tration could be highly informative to better understand
both their direct and indirect immune activity [4,48].
Finally, dissecting the molecular mechanisms behind
MSC-mediated immune suppression could open innova-
tive therapeutic avenues based on the use of these cell-
derived bioactive factors as a drug instead of MSC them-
selves, as recently suggested for TSG-6 [29].
Conclusion
The design of relevant tools to control production pro-
cesses and final products and to follow up patients involved
in clinical trials is of major importance in any cell therapy-
based therapeutic approach. The field of MSCs has rapidly
evolved from the idea that they could differentiate in vivo
into various functional cell types to the notion that they
exert their beneficial potential through a poorly defined
combination of paracrine trophic and immunosuppressive
factors. Considering the complexity of these properties, the
production, controls, and clinical use of MSCs must take
place in interactive research and clinical networks, allowing
the definition of validated standards and an in-depth ana-
lysis of mechanisms underlying the positive and negative
clinical results in a prospective fully integrated approach.
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